• 1
    Grand RJ, Ramakrishna J, Calenda KA. Inflammatory bowel disease in the pediatric patient. Gastroenterol Clin North Am 1995; 24: 61332.
  • 2
    Marx G, Seidman EG. Inflammatory bowel disease in pediatric patients. Curr Opin Gastroenterol 1999; 15: 3225.
  • 3
    Seidman EG. Inflammatory bowel disease. In: Roy, C, Silverman, A, Alagille, D, eds. Pediatric Gastrointestinal Disease, 4th edn. St Louis: Mosby, 1996: 586605.
  • 4
    Kirshner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 81321.
  • 5
    Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone therapy in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895902.
  • 6
    Van Deventer SJH. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 4438.
  • 7
    Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 145566.
  • 8
    Braegger CP, Nichols S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 8991.
  • 9
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 102935.
  • 10
    Present DH, Rutgeers P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 11
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 7619.
  • 12
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 13
    Derkx B, Taminiau J, Radema S, et al. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet 1993; 342: 1745.
  • 14
    Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137: 1926.
  • 15
    Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95: 318994.
    Direct Link:
  • 16
    Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 7584.
  • 17
    Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 10411.
    Direct Link:
  • 18
    Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a Pediatric Crohn's Disease Activity Index. J Pediatr Gastroenterol Nutr 1991; 12: 43947.
  • 19
    Otley A, Loonen H, Parekh N, et al. Assessing activity of pediatric Crohn's disease: which index to use. Gastroenterology 1999; 116: 52731.
  • 20
    Barabino A, Castellano E, Gandullia P, et al. A girl with severe fistulizing Crohn's disease. Dig Liver Dis 2000; 32: 7924.
  • 21
    Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 346977.
    Direct Link:
  • 22
    Stephens MC, Shepanski MA, Mamula P, et al. Incidence of infusion reaction in patient receiving infliximab at a pediatric center. J Pediatr Gastroenterol Nutr 2001; 33: 3756.
  • 23
    Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97: 140814.
    Direct Link:
  • 24
    Maini R, Breedveld F, Kalden J, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 155263.
  • 25
    Kugathasan S, Itoh J, Byle JT, et al. Distinct mucosal T cell responses to IL-12 in early and late stage of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998; 27: 471.
  • 26
    Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-bind, placebo controlled trial. N Engl J Med 1992; 326: 14039.
  • 27
    Hyams JS. Infliximab treatment of Crohn's disease in children: is time to not go retro(spective). Am J Gastroenterol 2003; 98: 56.
    Direct Link:
  • 28
    Griffiths AM, Buller HB. Inflammatory bowel disease. In: Durie, PR, Hamilton, JR, Walker Smith, JA, Watkins, JB, eds. Pediatric Gastrointestinal Disease, 3rd edn. Hamilton: B.C. Decker Inc., 2000: 61352.